Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 7/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956692 | 0.92 | FPR2 (0.47) | FPR2PROKR1MMP1KCNH2F10 | |
| SCHEMBL7957015 | 0.85 | ACACB (0.41) | ACACBLIPGHRH3HCRTR1HCRTR2 | |
| SCHEMBL7947301 | 0.85 | ACACB (0.41) | ACACBLIPGHRH3HCRTR1HCRTR2 | |
| SCHEMBL5632542 | 0.85 | ACACB (0.43) | ACACBLIPGHRH3 | |
| SCHEMBL7961553 | 0.85 | ACACB (0.41) | ACACBLIPGHRH3HCRTR1HCRTR2 | |
| SCHEMBL7961497 | 0.81 | LIPG (0.60) | LIPGHRH3 | |
| SCHEMBL7956252 | 0.81 | LIPG (0.60) | LIPGHRH3 | |
| SCHEMBL7956524 | 0.81 | LIPG (0.60) | LIPGHRH3 | |
| SCHEMBL7956682 | 0.81 | ACACB (0.43) | ACACBLIPGHRH3 | |
| SCHEMBL7956662 | 0.81 | ACACB (0.55) | ACACBKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |